Breaking News, Collaborations & Alliances

Datopotamab Deruxtecan Gets U.S. Breakthrough Therapy Designation

The ADC was discovered by Daiichi Sankyo and is being jointly developed by AstraZeneca and Daiichi Sankyo.

Author Image

By: Charlie Sternberg

Associate Editor

Datopotamab deruxtecan (Dato-DXd) has been granted Breakthrough Therapy Designation (BTD) in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) with disease progression on or after treatment with an EGFR-tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy.   Datopotamab deruxtecan is a specifically engineered TROP2-directed DXd antibody drug conjugate (ADC) discovered by ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters